These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 28111042)

  • 21. [Immune-checkpoint and hemopathies].
    Burroni B; Broudin C; Damotte D; Laurent C
    Ann Pathol; 2017 Feb; 37(1):101-110. PubMed ID: 28161001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.
    Einstein DJ; McDermott DF
    Clin Adv Hematol Oncol; 2017 Jun; 15(6):478-488. PubMed ID: 28749908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Teo MY; Rosenberg JE
    Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges.
    Solinas C; Chanzá NM; Awada A; Scartozzi M
    Cancer Treat Rev; 2017 Feb; 53():138-145. PubMed ID: 28113097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting.
    Aggen DH; Drake CG; Rini BI
    Clin Cancer Res; 2020 May; 26(9):2087-2095. PubMed ID: 31948999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emerging role of immunotherapy in advanced urothelial cancers.
    Tabayoyong W; Gao J
    Curr Opin Oncol; 2018 May; 30(3):172-180. PubMed ID: 29553950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The immunotherapy revolution in genitourinary malignancies.
    U Gandhy S; Madan RA; Aragon-Ching JB
    Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
    Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
    Chau I
    Clin Cancer Res; 2017 Oct; 23(20):6002-6011. PubMed ID: 28615369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.
    Myint ZW; Goel G
    J Hematol Oncol; 2017 Apr; 10(1):86. PubMed ID: 28434400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunotherapy for Bladder Cancer].
    Büchler T
    Klin Onkol; 2017; 30(Supplementum3):6-9. PubMed ID: 29239187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
    Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
    Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
    Ullén A
    Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
    [No Abstract]   [Full Text] [Related]  

  • 35. An Overview of Emerging Immunotargets of Genitourinary Tumors.
    Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
    Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel immunotherapies in GU malignancies.
    Drakaki A; McDermott DF
    Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD1/PD-L1 Axis in Uro-oncology.
    Junker K; Eckstein M; Fiorentino M; Montironi R
    Curr Drug Targets; 2020; 21(13):1293-1300. PubMed ID: 32213156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
    Monneur A; Gonçalves A; Bertucci F
    Bull Cancer; 2018 Mar; 105(3):263-274. PubMed ID: 29455872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination immunotherapy in genitourinary malignancies.
    Hoffman-Censits J; Wilde L
    Curr Opin Urol; 2016 Nov; 26(6):523-8. PubMed ID: 27517637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combination radiotherapy-immunotherapy in genitourinary cancer].
    Ollivier L; Guimas V; Rio E; Vaugier L; Masson I; Libois V; Labbé M; Fradin D; Potiron V; Supiot S
    Cancer Radiother; 2021 Oct; 25(6-7):565-569. PubMed ID: 34391648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.